NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts
NCT01116232 2019-03-26Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationBarbara Ann Karmanos Cancer InstitutePhase 2 Terminated4 enrolled 4 charts
NCT01419795 2017-07-27Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantFred Hutchinson Cancer CenterPhase 2 Terminated3 enrolled 10 charts
NCT00818961 2013-12-18Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic CancerNorthside Hospital, Inc.Phase 2 Terminated36 enrolled 16 charts